Back to Search Start Over

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Authors :
Javle, Milind
Roychowdhury, Sameek
Kelley, Robin Kate
Sadeghi, Saeed
Macarulla, Teresa
Weiss, Karl Heinz
Waldschmidt, Dirk-Thomas
Goyal, Lipika
Borbath, Ivan
El-Khoueiry, Anthony
Borad, Mitesh J
Yong, Wei Peng
Philip, Philip A
Bitzer, Michael
Tanasanvimon, Surbpong
Li, Ai
Pande, Amit
Soifer, Harris S
Shepherd, Stacie Peacock
Moran, Susan
Zhu, Andrew X
Bekaii-Saab, Tanios S
Abou-Alfa, Ghassan K
Source :
The Lancet Gastroenterology & Hepatology; October 2021, Vol. 6 Issue: 10 p803-815, 13p
Publication Year :
2021

Abstract

Treatment options are sparse for patients with advanced cholangiocarcinoma after progression on first-line gemcitabine-based therapy. FGFR2fusions or rearrangements occur in 10–16% of patients with intrahepatic cholangiocarcinoma. Infigratinib is a selective, ATP-competitive inhibitor of fibroblast growth factor receptors. We aimed to evaluate the antitumour activity of infigratinib in patients with locally advanced or metastatic cholangiocarcinoma, FGFR2alterations, and previous gemcitabine-based treatment.

Details

Language :
English
ISSN :
24681253
Volume :
6
Issue :
10
Database :
Supplemental Index
Journal :
The Lancet Gastroenterology & Hepatology
Publication Type :
Periodical
Accession number :
ejs57705554
Full Text :
https://doi.org/10.1016/S2468-1253(21)00196-5